Skip to main content

Table 1 Patients’ demographics in the two study arms

From: Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency

  

Standard

Brachytherapy

 
  

n = 139

n = 135

 

Measurement

 

n (%)

n (%)

P-value**

Age (years)*

 

43.5 ± 13.6

40.0 ± 14.8

0.044

Gender

Male

104 (74.8)

94 (69.6)

 
 

Female

35 (25.2)

41 (30.4)

0.337

WHO histology

1-2

29 (20.9)

37 (27.4)

 
 

3

110 (79.1)

98 (72.6)

0.205

Stage

T3-4&N2-3

34 (24.5)

36 (26.7)

 
 

Others

105 (75.5)

99 (73.3)

0.676

Neoadjuvant chemo

Yes

120 (86.3)

119 (88.1)

 
 

No

19 (13.7)

16 (11.9)

0.652

  1. *Value is mean ± standard deviation. **P-values ≤ 0.05 are considered significant.
  2. P-values ≤ 0.05 are considered significant.